Omid Hamid, MD, on Improving Duration of Response in Refractory Melanoma With Lifileucel
The chief of research and immunotherapy at Cedars-Sinai The Angeles Clinic and Research Institute discussed updated data from the phase 2 C-144-01 study of the lifileucel TIL therapy.
"Lifileucel is a 1-time therapy. The toxicity is manageable and usually related to the preconditioning or the IL2. So, what you have is the ability to give a viable option to our patients that is a1-time option and can give durability of response.”
The investigational autologous tumor infiltrating lymphocyte (TIL) therapy lifileucel (Iovance Biotherapeutics) has demonstrated encouraging efficacy and a manageable safety profile in pooled data from 2 cohorts of patients with heavily pretreated advanced melanoma in the phase 2 C-144-01 (NCT02360579) clinical trial. Data from the study were presented at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, November 8-12, 2022, in Boston, Massachusetts, by Amod A. Sarnaik, MD, FACS, Moffitt Cancer Center.
Investigators found that lifileucel had an objective response rate of 31.4% in the 2 cohorts, with 9 complete responses and 39 partial responses. Median duration of response(DOR) was not reached at a median follow up of 36.5 months, and 41.7% of responding patients had a DOR of 24 months or more. Median overall survival (OS) was 13.9 months, and the 12-month OS rate was 54% (95% CI: 45.6%, 61.6%)
CGTLive spoke with the study's co-author Omid Hamid, MD, chief, research and immunotherapy, Cedars-Sinai - The Angeles Clinic and Research Institute, to learn more about the C-144-01 study and the lifileucel TIL therapy. He discussed the advantages of the therapy in melanoma and how the research forwards progress for immunotherapy in solid tumors as a whole.
Click here to read more coverage of SITC 2022.
